Cite
Clinical significance of 5-α reductase inhibitor and androgen deprivation therapy in bladder cancer incidence, recurrence, and survival: a meta-analysis and systemic review.
MLA
Kim, Aram, et al. “Clinical Significance of 5-α Reductase Inhibitor and Androgen Deprivation Therapy in Bladder Cancer Incidence, Recurrence, and Survival: A Meta-Analysis and Systemic Review.” Aging Male, vol. 23, no. 5, Dec. 2020, pp. 971–78. EBSCOhost, https://doi.org/10.1080/13685538.2019.1646238.
APA
Kim, A., Kim, M. S., Ahn, J.-H., Choi, W. S., Park, H. K., Kim, H. G., & Paick, S. H. (2020). Clinical significance of 5-α reductase inhibitor and androgen deprivation therapy in bladder cancer incidence, recurrence, and survival: a meta-analysis and systemic review. Aging Male, 23(5), 971–978. https://doi.org/10.1080/13685538.2019.1646238
Chicago
Kim, Aram, Min Seo Kim, Jae-Hak Ahn, Woo Suk Choi, Hyoung Keun Park, Hyeong Gon Kim, and Sung Hyun Paick. 2020. “Clinical Significance of 5-α Reductase Inhibitor and Androgen Deprivation Therapy in Bladder Cancer Incidence, Recurrence, and Survival: A Meta-Analysis and Systemic Review.” Aging Male 23 (5): 971–78. doi:10.1080/13685538.2019.1646238.